Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct (DAWN Trial)
Source: View publication →
In patients presenting with acute ischemic stroke 6 to 24 hours after being last known well, endovascular thrombectomy plus standard care significantly improved 90-day functional independence compared to standard care alone when selected via clinical-core mismatch.
Key Findings
Study Design
Study Limitations
Clinical Significance
The DAWN trial fundamentally revolutionized the management of acute ischemic stroke by extending the therapeutic window for mechanical thrombectomy from 6 hours up to 24 hours in appropriately selected patients. By demonstrating that salvageable brain tissue (penumbra) can persist well beyond the traditional 6-hour mark, it prompted a rapid update to global stroke guidelines and shifted the triage paradigm from a strict 'time-window' to a physiological 'tissue-window' approach.
Historical Context
Historically, intravenous thrombolysis was restricted to within 4.5 hours of stroke onset. In 2015, a suite of landmark trials (such as MR CLEAN, ESCAPE, and SWIFT PRIME) established the profound efficacy of stent-retriever mechanical thrombectomy for large-vessel occlusions within a strict 6-hour window. However, up to 40% of large-vessel strokes present beyond 6 hours or as 'wake-up' strokes with an unknown time of onset, leaving a massive gap in care. The DAWN trial, published alongside the DEFUSE 3 trial in early 2018, addressed this gap by proving that patients identified via advanced perfusion imaging could safely undergo endovascular rescue therapy up to 24 hours after their last known well time.
Guided Discussion
High-yield insights from every perspective
The DAWN trial uses a 'clinical-core mismatch' to select patients for thrombectomy. Physiologically, what does the 'mismatch' represent, and how do brain tissue survival mechanisms make a 24-hour treatment window biologically plausible?
Key Response
The mismatch represents the presence of a large ischemic penumbra (salvageable tissue with severe functional impairment, driving the high NIHSS score) surrounding a small infarct core (irreversibly dead tissue, seen on imaging). Robust collateral leptomeningeal blood flow is the primary mechanism that keeps this penumbra viable for up to 24 hours in 'slow-progressor' patients, making delayed reperfusion highly beneficial.
A 65-year-old patient wakes up with right-sided hemiplegia and severe aphasia (NIHSS 18) 14 hours after last known well. What specific imaging modalities and criteria must be met to qualify this patient for endovascular thrombectomy under the DAWN protocol?
Key Response
The patient needs a non-contrast CT to rule out hemorrhage, a CTA or MRA showing a large vessel occlusion in the ICA or M1 segment of the MCA, and advanced imaging (CT perfusion or diffusion-weighted MRI) demonstrating a clinical-core mismatch. This mismatch is defined by strict criteria integrating age, clinical severity (NIHSS greater than or equal to 10), and a small infarct core volume (e.g., less than 31 mL or 51 mL depending on age and NIHSS) typically calculated by automated software.
How do the selection criteria of the DAWN trial differ from those of the DEFUSE 3 trial regarding the definition of salvageable tissue, and how do these differences impact patient selection for late-window thrombectomy in borderline cases?
Key Response
DAWN utilizes a 'clinical-core' mismatch, relying on a high clinical deficit via NIHSS compared to a small imaging core volume. In contrast, DEFUSE 3 uses a strictly imaging-based 'perfusion-core' mismatch (ratio of critically hypoperfused tissue [Tmax >6s] to core volume). Consequently, some patients with a large perfusion lesion but a lower clinical deficit (e.g., NIHSS of 8) might qualify for DEFUSE 3's purely volumetric criteria but be excluded by DAWN's strict clinical severity thresholds.
The DAWN trial shifted the stroke treatment paradigm from a strictly 'time-based' window to a 'tissue-based' window. How should this paradigm shift influence our institutional protocols for the triage and transfer of wake-up strokes from community spoke hospitals to comprehensive stroke centers?
Key Response
Protocols must evolve so that severe wake-up strokes or late presenters (up to 24 hours) are not automatically excluded from intervention based on time alone. Systems of care must establish rapid access to automated perfusion imaging at community spoke hospitals, or enable immediate 'drip-and-ship' transfer protocols to comprehensive centers to identify 'slow-progressors' who remain highly eligible for life-altering thrombectomy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DAWN trial utilized a Bayesian adaptive design with a utility-weighted modified Rankin scale (mRS) as a co-primary endpoint. What are the methodological advantages and potential pitfalls of using a utility-weighted mRS compared to a traditional dichotomized mRS in acute stroke trials?
Key Response
A utility-weighted mRS incorporates patient-centered values for different disability states and treats the scale as a continuous variable, which significantly increases statistical power and detects treatment effects across the entire spectrum of disability. However, its pitfalls include complex clinical interpretability compared to a simple dichotomous endpoint (e.g., independent vs. dependent) and a heavy reliance on the subjective assumptions used to assign the utility weights to each mRS tier.
The DAWN trial was stopped early for efficacy after enrolling only 206 of the planned 500 patients. As a critical appraiser, what concerns does early stoppage raise regarding the estimation of the treatment effect, and how does the control group's performance influence this assessment?
Key Response
Trials stopped early for benefit risk overestimating the true treatment effect due to random high fluctuations, known as the 'winner's curse'. However, in DAWN, the control group's dismal rate of functional independence (13%) was entirely consistent with known natural history data for late-window LVOs. This mitigates the concern, bolstering confidence that the massive absolute risk reduction (36%) represents a genuine and robust physiological benefit, even if the exact magnitude is slightly inflated.
Given the robust findings of the DAWN trial, how should current AHA/ASA guidelines reflect the use of mechanical thrombectomy in the 6 to 24-hour window, and what specific resource requirements must be recommended for stroke centers to safely implement this evidence?
Key Response
Following DAWN and DEFUSE 3, the AHA/ASA updated guidelines to provide a Class I, Level A recommendation for mechanical thrombectomy in selected patients 6 to 24 hours from last known well. To implement this safely and avoid futile recanalization, guidelines must simultaneously mandate that treating centers have 24/7 access to advanced neuroimaging (CTP or DW-MRI) and automated image processing software to accurately calculate core volumes for precise patient selection.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN Trial
Tested
Intraarterial treatment (predominantly thrombectomy) plus usual care
Population
Patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion within 6 hours of onset
Comparator
Usual care alone
Endpoint
Modified Rankin scale score at 90 days
ESCAPE Trial
Tested
Rapid endovascular treatment plus standard care
Population
Patients with acute ischemic stroke and small infarct core on imaging up to 12 hours after symptom onset
Comparator
Standard care alone
Endpoint
Modified Rankin scale score at 90 days
DEFUSE 3 Trial
Tested
Endovascular thrombectomy plus standard medical therapy
Population
Patients with acute ischemic stroke and target mismatch profile on imaging 6-16 hours after last known well
Comparator
Standard medical therapy alone
Endpoint
Modified Rankin scale score at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis